Department of Oral and Maxillofacial Surgery, Clinical Sciences, Graduate School of Comprehensive Human Science, University of Tsukuba, Tsukuba, Japan.
Bone Marrow Transplant. 2012 May;47(5):725-30. doi: 10.1038/bmt.2011.171. Epub 2011 Aug 29.
Oral mucositis (OM) is a frequent adverse effect of allogenic or autologous hematopoietic SCT. It results from direct toxic injury to the mucosal epithelial cells by the immunosuppressive regimen. Here, we compared the incidence and severity of OM between a group of 24 patients who received proper oral management during hematopoietic SCT and a group of 24 who did not. The oral management group received pre-hematopoietic SCT instruction on oral care and an oral examination in the clean room. Differences in the incidence and severity of OM between the two groups were examined statistically. OM was observed in 14 (58.3%) patients in the oral management group and 22 (91.6%) in the control group. The median of the OM score was 1 for the oral management group (range 0 to 3) and 2 for the control group (range 0 to 3). There was a significant difference in the OM score (P<0.05) and in the incidence of OM between the two groups (P<0.01). This study shows that oral management may decrease the occurrence of OM. Our results also suggest that it is important to include an oral management provider on the hematopoietic SCT team.
口腔黏膜炎（OM）是异基因或自体造血干细胞移植（HSCT）的常见不良反应。它是由免疫抑制方案对黏膜上皮细胞的直接毒性损伤引起的。在这里，我们比较了 24 名在造血干细胞移植期间接受适当口腔管理的患者组和 24 名未接受口腔管理的患者组之间 OM 的发生率和严重程度。统计分析了两组之间 OM 发生率和严重程度的差异。口腔管理组中有 14 名（58.3%）患者出现 OM，对照组中有 22 名（91.6%）患者出现 OM。口腔管理组的 OM 评分中位数为 1（范围 0 至 3），对照组为 2（范围 0 至 3）。两组 OM 评分（P<0.05）和 OM 发生率（P<0.01）存在显著差异。这项研究表明，口腔管理可能会降低 OM 的发生。我们的结果还表明，在造血干细胞移植团队中纳入口腔管理提供者非常重要。
